Therapeutic target for aggressive cancers discovered through CRISPR
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
List view / Grid view
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
By combining machine learning and T-cell engineering researchers were able to develop cell therapies that can selectively and effectively target and destroy solid tumours.
Upregulation of the c-Cbl gene causes degradation of the immune checkpoint protein PD-1 and may provide a possible new avenue for cancer therapies, according to researchers.
Researchers have identified the molecular mechanism that causes kidney cancer to resist drug treatment...
A research team have discovered that in the Cancer Genome Atlas database the gene expression in reference samples differs from normal tissue, depending on where in the kidney the samples happen to have been taken from...
Research in the field of kidney cancer, also called renal cancer, is vital, because many patients with this disease still cannot be cured today.
Kidney cancer rates have increased by 40% over the last 10 years in the UK, and the rise is expected to continue. An estimated 20,000 kidney cancer cases have been caused by obesity over the last decade in England, according to new figures from Cancer Research UK.